Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Intraocular delivery of ketorolac will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University
• Treatments: Ketorolac; Ketorolac Tromethamine

Criteria

Inclusion Criteria:

• Adult volunteers

• Chronic intractable uveitis or chronic complications of uveitis (macular edema)despite maximal medical treatment

• Unable to tolerate corticosteroids due to side effects

Exclusion Criteria:

• 18 years or younger

• Have active ocular infection

• Pregnancy